An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bone Biologics Corporation (NASDAQ: BBLG), specializing in orthobiologic products for spine fusion, will have its president and CEO, Jeffrey Frelick, present at the 2022 Virtual Growth Conference by Maxim Group LLC from March 28-30, 2022. A pre-recorded presentation will be accessible for 72 hours starting March 28 at 9:00 a.m. ET. Interested individuals can view the presentation via the company's investor relations page or directly on the conference's site.
Bone Biologics focuses on innovative bone regeneration solutions, particularly using the Nell-1 protein for spinal fusion and other applications.
Positive
None.
Negative
None.
BURLINGTON, Mass.--(BUSINESS WIRE)--
Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company’s president and chief executive officer, has been invited to present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30, 2022. A pre-recorded presentation will be available for 72 hours beginning Monday, March 28th at 9:00 a.m. Eastern time. Interested parties may access a webcast of the presentation on the investor relations section of the Company’s website and at this link.
The conference will be live on M-Vest. To attend, sign up here to become an M-Vest member.
About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking groundbreaking work with select strategic partners, building on unprecedented research on the Nell-1 protein that has produced a significant number of studies and publications in peer reviewed scientific literature. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion and has rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.
